[OncoTargets and Therapy] In this review, researchers summarize use, indications, and clinical safety and efficacy of olaparib, a PARP inhibitor, in the treatment of ovarian cancer, including in patients with BRCA mutations.
Some experts say the talc study’s data limitations weaken its impact in the field.
In this first reported prospective study, researchers compared outcomes of fertility-sparing surgery with radical surgery in women with stage I nonepithelial ovarian cancer.
Benefit substantial for homologous-recombination deficiency positive tumors with, without BRCA mutations.
And elevated CA125 indicates higher risk for other cancers, especially in women aged ≥50 years.